-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Alto Neuroscience, Raises Price Target to $37

Benzinga·08/13/2026 10:12:54
语音播报
BTIG analyst Thomas Shrader maintains Alto Neuroscience (NYSE:ANRO) with a Buy and raises the price target from $28 to $37.